26
November 2024
Microsaic Systems
plc
("Microsaic", "Microsaic Systems" or the "Company")
Operational
Update
Microsaic Systems plc (AIM: MSYS),
an international developer and provider of testing solutions for
unique and underserved public health and environmental markets, is
pleased to present an operational update.
As recently presented in the interim update
issued on 12 November 2024 ("H1 24
Interims"), the Company is focused on developing a strong
business in the water and environmental testing markets. Given the
unique position of its small-scale technologies the Company
believes it can become a leading mobile and point-of-use water
testing technology provider. The Company's technologies are
versatile and can provide testing results in minutes rather than
hours and can be summed up as a "lab in a box."
The Company is working on the following
operational and product development projects in the water and
environmental testing markets, focused on generating early revenues
and improvements in gross margins.
Qatar project
update
Further to its announcement of 27 March 2024,
the Company is pleased to confirm that all 27 Continuous Toxic
Monitoring systems (CTMs) have now been installed in Doha.
Commissioning is underway with the Company's regional partner,
Avanceon, which is a leading installer of industrial solutions,
including for the water industry, with a wide presence in Asia and
Middle East countries.
The Company's CTM network in Doha will
constantly monitor the region's potable water and is an early
warning system for the presence of any toxic chemicals present
enabling fast network shutdown if needed. Over 2,700 potential
toxins have been scientifically identified that can be detected by
the MicroTox® reagents used in the CTMs and is therefore one of the
most comprehensive systems on the market. All related consumables
are expected to be shipped by the end of the year for project
completion.
The end user, Kahramaa (Qatar General
Electricity and Water Corporation), is currently undergoing
training to operate the CTMs and final acceptance is expected soon
after. The total value of this contract to the Company is €571k and
the Company has invoiced 80% of the total amount in two tranches
for work completed. A second phase of the project is already under
discussion for 2025, which could mean the purchase of more CTMs for
new sites in Qatar.
MicroTox®
Instrumentation upgrades
The Company has significantly invested in
upgrading the design and operation of its MicroTox® driven devices.
This brings them up to date with the latest electronics to meet
customer requirements, including improved user interfaces. The
Company believes the upgrades are expected to result in an increase
in sales of instruments all of which use various forms of our
MicroTox® reagents.
MicroTox®
LX
Production has just started of our newly
upgraded laboratory based MicroTox® LX device having received
initial firm orders of eight units, with five to be shipped in
December to international customers. The MicroTox® LX is an
industry standard laboratory device for early screening of toxins
in water. Showcased initially at Weftec (largest North America
water industry exhibition) in October the upgraded MicroTox® LX is
attracting considerable industry interest turning into firm orders
and sales.
MicroTox®
FX
The Company is evaluating wider market interest
in its small handheld instrument which can be used for screening
potable water in real-time, in the field, called MicroTox® FX. For
possible military use the MicroTox® FX is being showcased in Q1
2025 at the permanent UK Defence and Security Exports exhibition
site at Larkhill, England, where allied overseas armed forces can
examine and try new products suitable for military use.
Tethys Purity®
Initiative
'Tethys Purity®' is a system of
multi-instruments and MicroTox® reagents solutions for
online/automated water safety testing. Instruments from Modern
Water, Microsaic Systems, and other selected partners are being
networked to deliver bespoke solutions to customers that require
constant live and online data monitoring capability.
The networking of the Tethys Purity® devices
for continuous centralised dashboard data monitoring and analysis
using machine learning software (AI) is currently under review. The
Company, in collaboration with Siemens and their technical support
provider CAD-IT, is starting trials of their specialist software
for the digital transformation and centralised data recording of
the Company's instruments. The Company is planning to launch the
Tethys Purity® system in early 2025. The Company is working with
regional offices of the British Department for Business and Trade
(DBT) to promote the Tethys Purity® solution in GCC countries and
elsewhere.
Pathogen
Detector Development & Consortium
The Company's new Pathogen Detector system,
initially designed by Microsaic Systems as a Covid-19 detector in
water, is being repurposed to detect Cryptosporidium (found in
sewage polluted water) initially and later multiple (possibly up to
nine) water-borne pathogens at the same time. As previously
announced, the Company will be working with Aptamer Group plc (in
York, England) supported by other specialist contractors to develop
the detector system.
The system will be portable and easily
transportable therefore offering a significant step forward for
in-line real-time detection and identification of multiple
pathogens including viruses. The Company believes this system will
be unique and allow customers to detect pathogens in water tailored
to their needs for fast response analysis in minutes.
The Company expects to move the project to
proof-of-concept shortly and commercialisation could be planned,
subject to resources, by the end of 2025.
PFAS &
Acrylamide Systems
Polyfluoroalkyl (PFAS)
substances are a group of manmade chemicals
designed to be non-stick, waterproof, and flame-resistant that have
been linked to various health problems, including certain
cancers which are of major concern in key
markets like the US. The Company's Microsaic
mass-spectrometer technology is well positioned to address this
market due to its portability and accuracy of testing (parts per
trillion) and aims to be the leading 'point of use' system for PFAS
detection and measuring systems. The Company believes this
embryonic but rapidly developing market provides another example
where its unique and proprietary technology can service a current
unmet need for very small minimum detection systems.
Despite the testing challenges posed by PFAS,
the Board believes this testing market could be a significant
opportunity for its system. Companies that can offer innovative,
cost-effective solutions will find themselves in high demand in a
market that is already growing rapidly. The
global PFAS
testing market was valued at $336
million in 2023, and it is expected to grow at a CAGR of 9.33% and
reach $893 million by 2034 (Source: Market Research.Com 8 October
2024).
A wide range of PFAS chemicals, including the
most common ones found in the environment, can be detected by the
Company's system and the Company is working with Swansea University
to identify and analyse the broadest range of PFAS chemicals
possible. The Company can also confirm it is in early-stage
partnership discussions with multiple companies also interested in
this important environmental market.
The Company continues to monitor the market for
detection of potentially carcinogenic acrylamide in heat treated
foods. Customer trials of our detection equipment based on the
MiD4500 mass spectrometer are expected to begin in H1 2025
collaborating with a specialist partner in combination with their
automated sample preparation method for testing for acrylamide in
crisp products.
MiD4500
Manufacturing
The Company has decided to reduce manufacturing
costs and improve the profitability of the Company's mass
spectrometer MiD4500 by ceasing subcontract manufacturing and bring
manufacturing in-house. The Company will open a smaller in-house
manufacturing facility in Woking, England, which will be
considerably lower-cost, more adaptable and capable of building the
new PFAS Detector as market demand develops.
The Company has also recently appointed a new
European distributor, Avantor, which is now trained on the system
for new customers in Europe. Avantor is a leading life science
tools company and global provider of mission critical products and
services to the life sciences and advanced technology
industries.
Sulphate
Reducing Bacteria Kits
The Company has seen growing demand in the
Middle East Gulf region and elsewhere for Sulphate-Reducing
Bacteria test kits (SRB kits), which were previously sold under the
QuickChek® brand. The Company has therefore acquired the design and
rights to manufacture and supply QuickChek® through the acquisition
of its Modern Water business in January 2024. Production is
expected to start in 2025.
Board
Composition
The Company recognises that good corporate
governance is important both for the interests of shareholders and
to support the future growth of the business. The Board is
committed to strengthening the Board through the addition of at
least one reputable, skilled and sector experienced independent
non-executive director to the board in early 2025.
Cash
The Company confirms that there has
been no material change to its current cash
position and cash flow forecasts remain as presented in
its H1 24 Interim update on 12 November 2024."
Comment
Bob Moore, Microsaic Systems' Acting Executive
Chairman, commented: "We are
cognisant and appreciative that shareholders have had to be very
patient with us over the past year. With a small but highly skilled
team we have been busy stabilising the business and unlocking the
substantial potential of our Company demonstrated by how contracts,
such as the one in Qatar, are developing. We have been through a
period of considerable restructuring and required capital
investment in our comprehensive and new product range, and we are
very encouraged by the nature of enquiries and rewards that are
coming our way. We look forward to providing further updates to the
market in due course."
Microsaic Systems plc
Bob Moore, Acting Executive
Chairman
|
+44 (0) 20 3657
0050
via Turner
Pope
|
|
|
Singer Capital Markets (Nominated Adviser & Joint
Broker)
Alex Bond / Oliver Platts
|
+44 (0)20 7496
3000
|
|
|
Turner Pope Investments (TPI) Limited (Joint
Broker)
Andy Thacker / James Pope
|
+44 (0) 20 3657
0050
|
About Microsaic Systems Group
Microsaic is highly experienced in the
development, manufacture and supply of microelectronics
instrumentation for markets requiring analytical testing in public
and environmental health markets. The Company has recently acquired
and integrated the assets of Modern Water with Microsaic Systems'
technologies resulting in comprehensive water testing and other
toxic testing capabilities. Microsaic's products and solutions are
commercially available through global markets via a network of
regional and country specific distributors and partners.